Cargando…

Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma

Glioblastoma (GBM) is the most common malignant primary brain cancer in adults. It is always resistant to existing treatments, including surgical resection, postoperative radiotherapy, and chemotherapy, which leads to a dismal prognosis and a high relapse rate. Therefore, novel curative therapies ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Tingyu, Song, Yixuan, Gu, Lingui, Wang, Yu, Ma, Wenbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503554/ https://www.ncbi.nlm.nih.gov/pubmed/37720174 http://dx.doi.org/10.2147/IJGM.S418837

Ejemplares similares

Gene Targets of CAR-T Cell Therapy for Glioblastoma
por: Wang, Chaoqun, et al.
Publicado: (2023)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Prospective approaches to enhancing CAR T cell therapy for glioblastoma
por: Choi, Sun Il, et al.
Publicado: (2022)

Current Progress in CAR-T Cell Therapy for Solid Tumors
por: Ma, Shuo, et al.
Publicado: (2019)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression
por: Luksik, Andrew S., et al.
Publicado: (2023)

Emerging Novel Combined CAR-T Cell Therapies
por: Nguyen, Anh, et al.
Publicado: (2022)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

Current progress in CAR-T cell therapy for tumor treatment
por: Chen, Lei, et al.
Publicado: (2022)

CAR-T Cell Therapy
por: Ahmad, Aamir
Publicado: (2020)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

From bench to bedside: the history and progress of CAR T cell therapy
por: Mitra, Aroshi, et al.
Publicado: (2023)

Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma
por: Cui, Jing, et al.
Publicado: (2020)

Glioblastoma Bystander Cell Therapy: Improvements in Treatment and Insights into the Therapy Mechanisms
por: Guerra-Rebollo, Marta, et al.
Publicado: (2018)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
por: Li, Tianjiao, et al.
Publicado: (2019)

CAR-T cell combination therapy: the next revolution in cancer treatment
por: Al-Haideri, Maysoon, et al.
Publicado: (2022)

Combining chemotherapy with CAR-T cell therapy in treating solid tumors
por: Wang, Arthur Xuan, et al.
Publicado: (2023)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Current Progress of CAR-NK Therapy in Cancer Treatment
por: Pang, Zhaojun, et al.
Publicado: (2022)

Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors
por: Xu, Jinjing, et al.
Publicado: (2018)

Base-edited CAR T cells for combinational therapy against T cell malignancies
por: Georgiadis, Christos, et al.
Publicado: (2021)

Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma
por: Chalise, Lushun, et al.
Publicado: (2022)

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma
por: Strecker, M.I., et al.
Publicado: (2022)

CAR T Cell Therapy for Neuroblastoma
por: Richards, Rebecca M., et al.
Publicado: (2018)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
por: Wang, Yuekun, et al.
Publicado: (2020)

Donor T cells for CAR T cell therapy
por: Tang, Tiffany C. Y., et al.
Publicado: (2022)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma
por: Maggs, Luke, et al.
Publicado: (2021)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

The Application of Nanobody in CAR-T Therapy
por: Bao, Chaolemeng, et al.
Publicado: (2021)

CAR-T Cell Therapy: From the Shop to Cancer Therapy
por: Uscanga-Palomeque, Ashanti Concepción, et al.
Publicado: (2023)

Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation
por: Sun, Ting, et al.
Publicado: (2023)

China enters CAR-T cell therapy era
por: Cao, Xin, et al.
Publicado: (2021)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a1up21ka0e1na4dvj974scoiq5